Raltegravir: The first HIV integrase inhibitor

This publication has 19 references indexed in Scilit:

• Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
  Journal of Medicinal Chemistry, 2008
• Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
  New England Journal of Medicine, 2008
• Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
  AIDS, 2007
• Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
• Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme
  Drug Metabolism and Disposition, 2007
• Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects
  Clinical Pharmacology & Therapeutics, 2007
• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
  The Lancet, 2007
• Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
• The Hunt for HIV-1 Integrase Inhibitors
  AIDS Patient Care and STDs, 2006
• Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
  Science, 2000